|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Other receivables | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Tax incentive receivable | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Right of use asset | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| In-process research and development and intangible assets, net | ||||||||||||||||||||
| Other long-term assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders' Equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Term debt | ||||||||||||||||||||
| Contingent value rights | ||||||||||||||||||||
| Lease obligations, current | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Convertible term loan | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long term Liabilities: | ||||||||||||||||||||
| Term debt | ||||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||||
| Contingent value rights | ||||||||||||||||||||
| Lease obligations | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||||
| Preferred stock, $0.0001 par value; authorized, 10,000,000 shares at June 30, 2022 and December 31, 2021; no shares issued or outstanding at June 30, 2022 and December 31, 2021 | ||||||||||||||||||||
| Seed Preferred Shares | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Total preferred stock, $0.0001 par value; authorized, 10,000,000 shares at June 30, 2022 and December 31, 2021; no shares issued or outstanding at June 30, 2022 and December 31, 2021 | ||||||||||||||||||||
| Common Stock, $0.0001 par value; authorized 200,000,000 shares at June 30, 2022 and December 31, 2021; 21,584,723 and 20,874,590 shares issued and outstanding at June 30, 2022 and December 31, 2021 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
